Free Newsletter
NICE snubs Orencia, picks 3 rivals
Free newsletter via e-mail
Tools
It's final: Britain's National Health Service won't pay for Bristol-Myers Squibb's anti-arthritis drug Orencia. Patient advocacy groups had been lobbying the National Institute for Health and Clinical Excellence to reconsider its earlier recommendation to pass over the drug because it's too expensive.
Meanwhile, NICE recommended Abbott Laboratories' Humira, Amgen's Embrel, and Johnson & Johnson's Remicade for treatment-resistant arthritis. Individual patients will be monitored every six months to make sure the drugs are working; if not, they'll be discontinued.
-read the news release from NICE (pdf)
-read NICE's guidance at its website
-read the story in The Guardian
-read more in the Independent
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
